Yokoyama Masaaki, Ohnishi Hiroaki, Ohtsuka Kouki, Matsushima Satsuki, Ohkura Yasuo, Furuse Junji, Watanabe Takashi, Mori Toshiyuki, Sugiyama Masanori
Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.
Department of Laboratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.
Jpn Clin Med. 2016 Dec 13;7:33-39. doi: 10.4137/JCM.S40549. eCollection 2016.
The aim of this study was to identify the unique molecular characteristics of biliary tract cancer (BTC) for the development of novel molecular-targeted therapies.
We performed mutational analysis of , , , and and immunohistochemical analysis of EGFR and TP53 in 63 Japanese patients with BTC and retrospectively evaluated the association between the molecular characteristics and clinicopathological features of BTC.
mutations were identified in 9 (14%) of the 63 BTC patients; no mutations were detected within the analyzed regions of , , and . EGFR overexpression was observed in 5 (8%) of the 63 tumors, while TP53 overexpression was observed in 48% (30/63) of the patients. Overall survival of patients with mutation was significantly shorter than that of patients with the wild-type gene ( = 0.005). By multivariate analysis incorporating molecular and clinicopathological features, mutations and lymph node metastasis were identified to be independently associated with shorter overall survival (, = 0.004; lymph node metastasis, = 0.015).
Our data suggest that mutation is a poor prognosis predictive biomarker for the survival in BTC patients.
本研究的目的是确定胆管癌（BTC）独特的分子特征，以开发新型分子靶向疗法。
我们对63例日本BTC患者进行了 、 、 及 的突变分析，以及EGFR和TP53的免疫组化分析，并回顾性评估了BTC分子特征与临床病理特征之间的关联。
63例BTC患者中有9例（14%）检测到 突变；在 、 及 的分析区域内未检测到 突变。63例肿瘤中有5例（8%）观察到EGFR过表达，而48%（30/63）的患者观察到TP53过表达。 突变患者的总生存期显著短于野生型 基因患者（ = 0.005）。通过纳入分子和临床病理特征的多因素分析，确定 突变和淋巴结转移与较短的总生存期独立相关（ 突变， = 0.004；淋巴结转移， = 0.015）。
我们的数据表明， 突变是BTC患者生存预后不良的预测生物标志物。
